Dr. Sahn oversees a range of collaborations aimed towards the discovery and development of small molecule chemical tools and drug leads for neurodegenerative diseases and neurological disorders. Sahn’s research team is currently developing chemical modulators of transmembrane proteins within the central nervous system (CNS) that have neuroprotective and cognition-enhancing properties. The group has developed a preclinical lead compound that restores cognitive function in transgenic Alzheimer’s disease (AD) mice and improves cognitive performance in non-diseased animals. The team recently identified a promising tool compound that enhances learning and memory in mice following a traumatic brain injury (TBI), while also preventing axonal degeneration and neuron and oligodendrocyte death. Optimized leads for TBI are under development for IND-enabling studies. Preclinical lead compounds have also been developed for the treatment of neuropathic pain by a new mode of action. These compounds may represent a much-needed pharmacological solution to pain management that is devoid of the neurocognitive- and addictive properties associated with the current standard of care drugs. In another program, Sahn and his team are developing small molecules that reduce alcohol consumption in ethanol dependent rats. These compounds function via a mechanism of action not previously associated with alcohol dependence and are currently being refined for improved ADME-Tox and PK properties.